Dans cette déclaration de consensus datée du 28 avril 2022, le Conseil HPV du CHIC accueille favorablement la conclusion du SAGE de l’OMS selon laquelle un vaccin anti-papillomavirus à dose unique confère une protection solide, comparable à un schéma à deux ou trois doses, et appelle les programmes nationaux de vaccination et les organes consultatifs […]
Topic: 3. The vaccine
CHIC HPV Council Consensus Statement on One-Dose Recommendation
In this consensus statement dated April 28, 2022, the CHIC HPV Council welcomes the WHO SAGE conclusion that a single-dose HPV vaccine delivers solid protection comparable to two- or three-dose schedules, and urges national immunization programmes and policy bodies to act on this recommendation. The Council highlights benefits for girls and families (comparable protection), programme […]
Evidence for an HPV one-dose schedule
In this review, Stanley and colleagues examine the biological plausibility and clinical trial evidence supporting a single-dose HPV vaccination schedule. The authors synthesize data from randomized controlled trials—including KEN SHE (Kenya), DoRIS (Tanzania), the Costa Rica Vaccine Trial, and the IARC India trial—demonstrating high and durable efficacy comparable to multi-dose regimens. Post-licensure observational studies and […]
Communication And Dialogue With Islamic Religious Scholars: A Focus Group Discussion To Enhance Human Papillomavirus Vaccine Awareness And Uptake In Northern Nigeria
In northern Nigeria, a focus group discussion with 13 senior Islamic scholars (Imams) from diverse ideological backgrounds was conducted in Gombe one week before the state’s HPV vaccine launch in May 2024, with the aim of surfacing barriers to vaccine acceptance and building religious endorsement ahead of rollout. Scholars reached consensus that Islam permits — […]
HPV Vaccination PHPV Vaccination Determinant in Cameroon: A Cross-Sectional Nationwide Health Workers Survey
In Cameroon, HPV vaccination coverage remained below 20% until 2023, when the introduction of a single-dose gender-neutral schedule combined with periodic intensification of routine immunisation (PIRI) raised coverage to approximately 60% among girls. A nationwide cross-sectional survey of 1,225 health workers conducted between August 2023 and July 2024 found that 83% were willing to vaccinate […]
Financing and Policy Dynamics in HPV Vaccine Uptake: Insights from Kenya’s Gavi Transition and Single-Dose Introduction
In Kenya, a retrospective analysis of HPV Dose 1 data from the national health information system (2019–2025) reveals a pronounced cyclical uptake pattern, with quarterly doses ranging from a low of 21,764 (Q1 2025) to a peak of 564,403 (Q4 2021), with surges consistently linked to intensified outreach campaigns and school calendar alignment and sharp […]
Does a single-dose HPV vaccine regimen deliver program cost savings? Real-world evidence from Ethiopia
In Ethiopia, a retrospective microcosting study of the late 2024 HPV vaccine multi-age cohort (MAC) campaign — targeting girls aged 9–14 across 82 health facilities in four regions — estimated the financial cost of delivering a single dose at US$0.66 and the economic cost at US$1.67 per fully vaccinated girl, excluding vaccine and immunization supply […]
Leaving 22 million girls unprotected from HPV: Impact of adopting a single-age target with low vaccination coverage in Kenya
In Kenya, a static cohort modelling study evaluated 12 HPV vaccination policy scenarios to inform the country’s cervical cancer elimination trajectory toward 2030. A prompt switch to a single-dose strategy combined with rapid coverage scale-up would avert an additional 249,700 DALYs compared with the current two-dose programme at approximately 50% coverage, while simultaneously reducing both […]
Policy, Schedule and Vaccine Product Choice: Q&A Session
The Q&A session highlighted critical considerations for transitioning to single-dose HPV vaccination, including evidence needs for NITAG decision-making, updates on ongoing trials like HANDS, and the unique immunological advantages of virus-like particle vaccines. Participants raised concerns about vaccine efficacy in older adolescents, genotype distribution differences (e.g., HPV 52 prevalence), and implications for vaccine selection. Discussions […]
Nepal – National introduction of HPV vaccination, including monitoring
Nepal’s HPV vaccination campaign, launched on 4 February 2025, targeted 1.6 million girls (grades 6–10 and out‑of‑school girls aged 10–14), achieving 94% coverage with single‑dose Cecolin. The program utilized 18,900 schools and 8,200 health facilities, with 51,483 female community health volunteers and 27,000 health workers mobilized. Youth‑led advocacy, child clubs, and digital social listening strategies […]